Glenview Trust Co purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 7,689 shares of the medical research company’s stock, valued at approximately $720,000.
Several other large investors have also recently made changes to their positions in EW. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new stake in shares of Edwards Lifesciences Corporation during the second quarter valued at $100,000. Spirit of America Management Corp NY bought a new stake in Edwards Lifesciences Corporation during the third quarter worth approximately $121,000. TCI Wealth Advisors Inc. increased its stake in Edwards Lifesciences Corporation by 30.5% in the third quarter. TCI Wealth Advisors Inc. now owns 1,044 shares of the medical research company’s stock worth $126,000 after buying an additional 244 shares during the period. Cornerstone Advisors Inc. increased its stake in Edwards Lifesciences Corporation by 28.9% in the third quarter. Cornerstone Advisors Inc. now owns 1,075 shares of the medical research company’s stock worth $130,000 after buying an additional 241 shares during the period. Finally, Quadrant Capital Group LLC increased its stake in Edwards Lifesciences Corporation by 8.6% in the third quarter. Quadrant Capital Group LLC now owns 1,203 shares of the medical research company’s stock worth $138,000 after buying an additional 95 shares during the period. 83.99% of the stock is owned by institutional investors.
Shares of Edwards Lifesciences Corporation (NYSE:EW) traded down 0.33% during mid-day trading on Friday, reaching $89.63. 391,163 shares of the company’s stock traded hands. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75. The company’s 50 day moving average is $94.40 and its 200 day moving average is $102.51. The company has a market cap of $19.15 billion, a P/E ratio of 34.34 and a beta of 0.53.
Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings data on Wednesday, February 1st. The medical research company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Edwards Lifesciences Corporation had a net margin of 19.22% and a return on equity of 25.00%. The business had revenue of $767.70 million for the quarter, compared to analyst estimates of $760.85 million. During the same period in the previous year, the firm earned $0.64 EPS. The business’s revenue for the quarter was up 14.4% compared to the same quarter last year. On average, analysts predict that Edwards Lifesciences Corporation will post $3.40 EPS for the current fiscal year.
This news story was originally reported by WKRB News and is the property of of WKRB News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark and copyright legislation. The correct version of this news story can be read at http://www.wkrb13.com/markets/1981549/glenview-trust-co-purchases-shares-of-7689-edwards-lifesciences-corporation-ew.html.
A number of equities research analysts have commented on EW shares. J P Morgan Chase & Co set a $120.00 target price on shares of Edwards Lifesciences Corporation and gave the stock a “buy” rating in a research report on Thursday, December 1st. Canaccord Genuity set a $140.00 target price on shares of Edwards Lifesciences Corporation and gave the stock a “buy” rating in a research report on Tuesday, November 22nd. Jefferies Group LLC reaffirmed a “buy” rating and issued a $115.00 target price (down previously from $125.00) on shares of Edwards Lifesciences Corporation in a research report on Wednesday, October 26th. Stifel Nicolaus cut their target price on shares of Edwards Lifesciences Corporation from $122.00 to $114.00 and set a “buy” rating for the company in a research report on Wednesday, October 26th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $110.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, October 28th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and nineteen have assigned a buy rating to the company’s stock. Edwards Lifesciences Corporation has an average rating of “Buy” and a consensus price target of $116.54.
In other Edwards Lifesciences Corporation news, CEO Michael A. Mussallem sold 49,100 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $84.67, for a total value of $4,157,297.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Kieran Gallahue bought 3,000 shares of Edwards Lifesciences Corporation stock in a transaction on Tuesday, November 29th. The stock was purchased at an average price of $84.63 per share, for a total transaction of $253,890.00. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 68,870 shares of company stock worth $1,604,434 and sold 187,928 shares worth $17,001,801. 2.37% of the stock is owned by insiders.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/1981549/glenview-trust-co-purchases-shares-of-7689-edwards-lifesciences-corporation-ew.html
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.